gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · PASGHealthcareBiotechnology

Passage Bio, Inc. Common Stock (PASG)

$3.46−1.42%
Close Nov 5, 2026 · split-adjusted
Nov 5, 2026$3.40▼ 48.87% in range
Nov 4, 2025Low $3.32 · High $19.85Nov 5, 2026
What changed · written from our data
As of Nov 5, 2026

Passage Bio closed at $3.46 on Nov 5, down 1.42%, 82.6% below its 52-week closing high. Volume of 28.1K shares was 1.73× its 20-day average (above normal).

Split-adjusted performance: -10.2% over one month, -15.2% over six months, -47.9% over one year.

Short interest was 68.9K shares at the Oct 15 settlement, down 24.1% from the prior report (2.4% of float, 3.5 days to cover).

Market cap$11.1M3.2M shares
Revenue · quarter$0.00—
Diluted EPS$-2.44—
P/E · TTM—
Net margin—
Dividend yieldNone
52-week range3.32 – 19.85−82.6% from high
Volume28.1K1.73× 20-day avg
Volatility · 60d77.2%Annualised
Short % of float2.4%3.5 days to cover
Net cash$24.2MCash $24.2M
Next earnings—Not scheduled
Split-adjusted performance
1W −1.7%1M −10.2%3M −21.4%6M −15.2%YTD −70.7%1Y −47.9%3Y −73.0%5Y −98.0%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Biotechnology

Percentile among 139 companies (100 = best)

6-month momentum58
Revenue growth—
Net margin—
Value (low P/E)—
Size9

Industry medians: 6-month return −24.8%, revenue growth +8.5%, net margin −226.4%, P/E 21.0×.

Short interest

Details →
Shares short68.9K−24.1% vs prior
Days to cover3.5Settled Oct 15
% of float2.4%
Short vol. 10d34.9%of daily volume

Closest peers by size in Biotechnology

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
PASGPassage Bio$3.46−1.42%−15.2%———$11.1M
SCLXScilex Holding$1.70−7.10%−78.9%−22.8%−1501.3%—$12.0MCompare
INTSIntensity Therapeutics$3.10−11.43%−39.3%———$10.1MCompare
TCRXTScan Therapeutics$0.1818−13.43%−85.0%−65.8%−2888.6%—$12.3MCompare
BCDABioCardia$0.8900−2.53%−18.3%———$13.5MCompare
DYAIDyadic International$0.3401−7.25%−54.3%−0.6%−221.0%—$13.6MCompare
ATYRaTyr Pharma$6.03−2.43%−83.6%———$15.1MCompare
INABIN8bio$0.8300−10.82%−48.1%———$8.2MCompare
ABOSAcumen Pharmaceuticals$0.2138−1.16%−91.3%———$15.5MCompare

News about Passage Bio

All news →
$HAREHOLDER ALERT: The M&A Class Action Firm Launches Investigation for the Merger — BWMN, UTZ , PASG and FNWDGlobeNewswire Inc. · Oct 27, 2026▼ Negative$HAREHOLDER ALERT: IS IT A FAIR DEAL FOR YOU? The M&A Class Action Firm Is Investigating the Merger — UTZ, SAFT, PASG and FNWDGlobeNewswire Inc. · Oct 20, 2026▼ Negative

Quick answers

What does Passage Bio do?
Passage Bio Inc is a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases. Their primary focus is the development and advancement of cutting-edge, one-time gene therapies designed to target critical underlying pathologies in these conditions.
What is PASG's market cap?
$11.13M, based on the Nov 5 close of $3.46.
Does Passage Bio pay a dividend?
No regular cash dividend has been paid in the last year.
How much of PASG is sold short?
68.9K shares, 2.4% of float, as of Oct 15, 2026.
What sector is PASG in?
Healthcare, in the Biotechnology industry.

About Passage Bio

Passage Bio Inc is a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases. Their primary focus is the development and advancement of cutting-edge, one-time gene therapies designed to target critical underlying pathologies in these conditions. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target the critical underlying pathology of neurodegenerative diseases. The pipeline having PBFT02.

HQ: Philadelphia, PA24 employeesListed Feb 28, 2020passagebio.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology